Atherosclerotic Cardiovascular Disease clinical trials

Explore recruiting atherosclerotic cardiovascular disease clinical trials.

Recruiting atherosclerotic cardiovascular disease studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Atherosclerotic Cardiovascular Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)

Spain, Hungary, Portugal, Greece, Germany, Italy +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)

France, Denmark, Germany, Spain, Italy, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effect of impact of PCSK9 inhibitor on coronary microvascular dysfunction in patients with atherosclerotic cardiovascular disease needing coronarography.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

Greece, Hungary, Poland, Germany, Slovakia, Denmark +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants with Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT trial)

Czechia, Netherlands, Italy, Spain, Hungary, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, placebo-controlled, parallel-group, investigator- and participant-blinded Phase 2a study to investigate the efficacy, safety, and tolerability of DFV890 and MAS825 for inflammatory marker reduction in an adult population with coronary heart disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Atherosclerotic Cardiovascular Disease trials by city

Atherosclerotic Cardiovascular Disease clinical trials

Recruiting atherosclerotic cardiovascular disease studies right now

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Predictive Value of Systolic Rise Time of the Plantar Arch on the Risk of Major Adverse Limb Events (MALE) and Major Adverse Cardiovascular Events (MACE) in Peripheral Artery Disease (PAD) at Critical Ischaemia Stage

Penn Medicine Healthy Heart

Impact of Treating Severe Periodontitis on Inflammatory Activity of Atheromatous Plaques in Patients With Acute Myocardial Infarction (AMI)

Evaluating the Safety and Efficacy of the G-stream® Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery

Serrantor OCT Study

Carnosine for Peripheral Arterial Disease Patients

Red Light Treatment in Peripheral Artery Disease

SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes

The Effects of Diet and Exercise Interventions in Peripheral Artery Disease

Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease

Leg Exercise Assistive Paddling (LEAP) Therapy for Peripheral Artery Disease

Also recruiting in Europe

A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)

Effect of impact of PCSK9 inhibitor on coronary microvascular dysfunction in patients with atherosclerotic cardiovascular disease needing coronarography.

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event

A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants with Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT trial)

Atherosclerotic Cardiovascular Disease trials by city

Other conditions